Capital Cube • 9 months agoProvectus Biopharmaceuticals, Inc. :PVCT-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016
Click here to see latest analysisProvectus Biopharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2016.AnalysisSummary numbers: Revenues of USD 0 million, Net Earnings of USD -8.51 million.The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.PVCT-US‘s earnings and EBITDA are […] (Read more...) The post Provectus Biopharmaceuticals, Inc. :PVCT-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 appeared first on CapitalCube.
TheStreet.com • 11 months ago
The extravagant travel-expense payouts to Provectus CEO Craig leaves the company at risk of criminal or civil investigations by the Securities and Exchange Commission.
Reuters • last year
Modern cancer drugs supercharge immune systems, target specific gene mutations and pack modified viruses into vaccines. Rose Bengal, a cheap industrial chemical that turns yarn and food bright red, has been used as a diagnostic staining agent for some time. Now, some scientists are looking at its potential to fight various forms of cancer.
PVCT : Summary for PROVECTUS BIOPHARM COM USD0.001 - Yahoo Finance
Provectus Biopharmaceuticals, Inc. (PVCT)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.02 - 0.03|
|52 Week Range||0.01 - 0.54|
|PE Ratio (TTM)||-0.16|
|Earnings Date||Mar 28, 2017 - Apr 3, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||3.50|